1. Home
  2. SNT vs LUNG Comparison

SNT vs LUNG Comparison

Compare SNT & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Senstar Technologies Ltd.

SNT

Senstar Technologies Ltd.

HOLD

Current Price

$2.67

Market Cap

65.6M

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.27

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNT
LUNG
Founded
1965
1995
Country
Canada
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Industrial Specialties
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
65.6M
57.9M
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
SNT
LUNG
Price
$2.67
$1.27
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$5.38
AVG Volume (30 Days)
14.1K
466.4K
Earning Date
04-23-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
$19.22
N/A
Revenue Growth
N/A
8.01
52 Week Low
$2.64
$1.13
52 Week High
$5.34
$3.88

Technical Indicators

Market Signals
Indicator
SNT
LUNG
Relative Strength Index (RSI) 30.45 45.58
Support Level N/A $1.27
Resistance Level $3.19 $1.45
Average True Range (ATR) 0.15 0.09
MACD -0.01 0.00
Stochastic Oscillator 6.93 39.33

Price Performance

Historical Comparison
SNT
LUNG

About SNT Senstar Technologies Ltd.

Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: